Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement
There are over 70 known lysosomal storage disorders (LSDs), most caused by mutations in genes encoding lysosomal hydrolases. Central nervous system involvement is a hallmark of the majority of LSDs and, if present, generally determines the prognosis of the disease. Nonetheless, brain disease is curr...
Main Authors: | Caroline Sevin, Kumaran Deiva |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2021.624988/full |
Similar Items
-
Optimization of viral transduction in the central nervous system
by: Burt, Daniel Robert
Published: (2016) -
Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain
by: Josse A. Depla, et al.
Published: (2020-09-01) -
Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
by: María José de Castro, et al.
Published: (2021-08-01) -
Viral vectors for gene delivery to the central nervous system
by: Thomas B. Lentz, et al.
Published: (2012-11-01) -
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
by: Marshall S. Goodwin, et al.
Published: (2020-03-01)